Oho, making his debut in the highest makuuchi division, is a grandson of Taiho, the late yokozuna of the Showa Era (1926-1989), who dominated sumo in postwar Japan. Oho’s father is ...

In an untitled letter issued last Friday and made public this week, the FDA took aim at clinical data included on a doctor-facing web page for Taiho Oncology’s Lytgobi. Lytgobi is an FGFR ...

Japan's Taiho Pharma has reached a deal to buy Switzerland's Araris Biotech, around 18 months after they started collaborating on the development of antibody-drug conjugates (ADCs) for cancer.

The Japanese pharmaceutical company Taiho Pharmaceutical is set to acquire the Swiss antibody-drug conjugate (ADC) company Araris Biotech for $400 million. Taiho and Araris have been collaborating ...

Only five sumo wrestlers, including the legendary yokozuna Taiho, have ever won 12 victories or more in their debut tournaments as sekiwake, and all went on to become yokozuna or ozeki.

Taiho Pharmaceutical Co., Ltd., an R&D-driven specialty pharma focusing on the fields of oncology and immune-related diseases, and Araris Biotech AG, a Swiss biotechnology company developing ...

AstraZeneca has tapped Korea's Alteogen to develop subcutaneous cancer drugs. Taiho Pharmaceutical is paying $400 million to acquire antibody-drug conjugate expert Araris Biotech. WuXi AppTec ...

“We’re open for business,” said Taiho Oncology, Inc. CEO, Timothy Whitten. Alongside its growing pipeline of orally administered oncology drugs, the US subsidiary of Japan’s Taiho ...

Investing.com -- On Monday, Taiho Pharmaceutical (TADAWUL:2070) Co., Ltd. announced a definitive agreement to acquire Araris Biotech AG, a Swiss biotech company specializing in next-generation ...

Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho Pharmaceutical") and Araris Biotech AG (hereinafter "Araris"), a Swiss biotechnology company developing next-generation antibody drug conjugates ...